Express Scripts CEO: “I Don’t Mind If Amazon Comes In”

The pharmacy benefit manager had a rosy view at the J.P. Morgan conference on the online retailer potentially entering the drug distribution market. That may be because CEO Wentworth views them as a partner.

Business teamwork puzzle pieces.

Rumors that [Amazon.com Inc.] could enter the drug distribution market and upend the way patients buy their drugs have been rampant, and it doesn’t look like they are going to die down in 2018. Express Scripts Holding Co. CEO Timothy Wentworth hinted Jan. 8 during the J.P. Morgan Healthcare Conference that the pharmacy benefit manager has talked with Amazon about pharmacy distribution, though he wouldn’t say if they have discussed collaborating outright.

Wentworth was asked if he could confirm whether or not Express Scripts has participated in any partnering discussions with Amazon...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Supply Chain

OneSource CEO On Next-Gen GLP-1 Innovator Talks, Xbrane And Viatris Partnering

 
• By 

OneSource Specialty CEO Neeraj Sharma discusses with Scrip exploratory talks with next-gen GLP-1 innovators, prospects for semaglutide generics and investment in Swedish firm Xbrane, among other topics.

50% Levy On India And Brazil, US Tariffs Leave Global Trade, Forecasts In Disarray

 
• By 

50% tariffs on US imports from India, a range on others, an uncertain outcome of Section 232 investigations of pharma and talk of BRICS tariffs are making forecasting for the pharma industry extremely difficult, Scrip finds in this infographic analysis

EU 15% Tariff Deal Still Leaves Questions For Pharma

 

A single 15% tariff rate on imports from Europe includes pharmaceuticals, but it remains unclear if the trade deal will exclude generics or if Trump will offer a grace period.

Cipla CEO On Tariff Threat: ‘We Have One Of The Most Well Diversified Models’

 

Cipla's leadership fields shareholder queries on the specter of US tariffs and also outlines how the firm is nurturing the business for the future in areas like mRNA and point-of-care diagnostics, while building on its strength in the respiratory space.

More from Business

Norway’s Nykode Upbeat About Cancer Vaccines After Tough Year

 
• By 

The firm is concentrating on its Keytruda combo for head and neck cancer after being abandoned by Roche and boardroom battles.

MannKind Snaps Up scPharmaceuticals In Cardiorenal Expansion

 

The deal, which could be worth as much as $360m, marks the Danbury, CT-based firm's strategic expansion into cardiorenal medicine.

Nippon Kayaku Aims To Broaden Portfolio Via Singaporean JV

 
• By 

Mid-sized, diversified Japanese group teams up with Singaporean wholesaler Formiica and Japanese trading/contract services firm CBC for Singapore JV focused on in-licensing in Asia/Oceania.